Skip to main content
Explore URMC
menu

Ajay Dhakal, M.B.B.S.

Contact Information

Phone Numbers

Appointment: (585) 487-1700

Fax: (585) 321-1724

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Setting

Cancer

Biography

Dr. Ajay Dhakal received his medical degree and completed his internship at Kathmandu Medical College in Kathmandu, Nepal in 2009. Dr. Dhakal then finished his residency at Maimonides Medical Center in Brooklyn, New York in 2015. He then completed a clinical fellowship at Roswell Park Comprehensive Cancer Center in Buffalo, New York in 2018.

Dr. Dhakal's special interest is breast cancer. His goal is to help breast cancer patients live longer with a good quality of life. Dr. Dhakal is passionate about conducting clinical research to better understand cancer biology and to discover new ways to treat breast cancer.

In his free time, Dr. Dhakal likes to travel and watch movies.

Credentials

Specialties

  • Hematology - American Board of Internal Medicine
  • Internal Medicine - American Board of Internal Medicine
  • Medical Oncology - American Board of Internal Medicine

Education

2009
MBBS | Kathmandu Medical College

Post-doctoral Training & Residency

07/01/2015 - 06/30/2018
Fellowship in Hematology/Oncology at Roswell Park Cancer Institute

07/01/2013 - 06/30/2015
Residency in Internal Medicine at Maimonides Medical Center

07/01/2012 - 06/30/2013
Internship in Internal Medicine at Maimonides Medical Center

VIEW ALL expand_more

Awards

2017 - 2018
Nominated for Gerald L. Logue Memorial Travel Award
Sponsor: Roswell Park Comprehensive Cancer Center,
Location: Buffalo, NY

2017
Best Poster, Annual Research Day
Sponsor: Jacobs School of Medicine and Biomedical Sciences
Location: University at Buffalo, Buffalo, NY

2014
Resident-Rock Award
Sponsor: Maimonides Medical Center
Location: Brooklyn, NY

2005
Dean's List in Basic Science Final Examinations
Sponsor: Kathmandu Medical College
Location: Nepal

2003 - 2009
Ministry of Education Scholarship
Sponsor: Kathmandu Medical College
Location: Nepal

VIEW ALL expand_more

Clinical Trials

The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib

Lead Researcher: Ajay Dhakal

This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.

View Study Details

EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers

Lead Researcher: Ajay Dhakal

The reason for this study is to see if the study drug LY3484356 alone or in combination with other anticancer therapies is safe and effective in participants with advanced or metastatic breast cancer or endometrial cancer.

View Study Details

(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response

Lead Researcher: Ajay Dhakal

This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after pre-operative chemotherapy and HER2-targeted therapy. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Trastuzumab and pertuzumab are both a form of "targeted therapy" because they work by attaching themselves to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When these drugs attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving paclitaxel, trastuzumab, and pertuzumab may enable fewer chemotherapy drugs to be given without compromising patient outcomes compared to the usual treatment.

View Study Details

MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Lead Researcher: Ajay Dhakal

The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enable additional study arms at low incremental effort and cost. FLEX Registry will utilize an adaptive design, where additional targeted substudies and arms can be added after the initial study is opened.

View Study Details

MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Lead Researcher: Ajay Dhakal

The purpose of this registry is to create a large-scale, population-based database. This database will match health information to genome data to identify new gene associations in breast cancer. The study will look at Agendia Breast Cancer tests, including MammaPrint® and BluePrint™, which are tests that help doctors analyze and profile breast cancer tumors.

View Study Details

A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently With Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer (S1706)

Lead Researcher: Ajay Dhakal

This phase II trial studies how well radiation therapy with or without olaparib works in treating patients with inflammatory breast cancer. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. It is not yet known whether radiation therapy with or without olaparib may work better in treating patients with inflammatory breast cancer.

View Study Details

Publications

Journal Articles

5/28/2021
Dhakal A, Falkson C, O'Regan RM. "Adjuvant cyclin-dependent kinase 4/6 inhibition in hormone receptor-positive breast cancer: One Monarch to rule them all?" Cancer.. 2021 May 28; Epub 2021 May 28.

1/25/2021
Zhang H, Moisini I, Turner BM, Wang X, Dhakal A, Yang Q, Kovar S, Schiffhauer LM, Hicks DG. "Significance of HER2 in Microinvasive Breast Carcinoma." American journal of clinical pathology.. 2021 Jan 25; Epub 2021 Jan 25.

7/15/2020
Moftakhar B, Lekkala M, Strawderman M, Smith TC, Meacham P, Fitzgerald B, Falkson CI, Dhakal A. "Impact of early dose intensity reduction of Palbociclib on clinical outcomes in patients with hormone-receptor-positive metastatic breast cancer." Breast cancer research and treatment.. 2020 Jul 15; Epub 2020 Jul 15.

Books & Chapters

2006
Book Title: Angel's Concise Clinical Methods,
Author List: Dhakal A, Magar A, Shrestha S, Shrestha R, Palikhey S
Published By: Makalu Publication House 2006 in Nepal

VIEW ALL PUBLICATIONS